ANIFROLUMAB IN THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS - A LITERATURE REVIEW
DOI:
https://doi.org/10.31435/ijitss.1(49).2026.4568Keywords:
Interferon Type I, Monoclonal Antibodies, Autoimmune Diseases, Pharmacokinetics, Systemic Lupus ErythematosusAbstract
Introduction and objective: Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease characterised by a diverse clinical course and multifactorial aetiology. Improvement in treatment has been significant in recent years. Current treatment is primarily based on glucocorticosteroids and immunosuppressive drugs that cause numerous side effects and have limited efficacy in a significant number of patients. Anifrolumab therapy is a new treatment option in SLE. The aim of this review is to describe its characteristics, mechanisms of action, and therapeutic effects.
Review methods: A literature review was conducted using scientific publications, focusing primarily on those published between 2017 and 2025. The PubMed and Google Scholar databases were used for the search. Publications in English and Polish that met thematic and substantive criteria were analyzed. Ultimately, 32 publications were included in the review
Brief description of the state of knowledge: Anifrolumab is a modern monoclonal antibody that blocks the type I interferon pathway, one of the key mechanisms in the pathogenesis of SLE. A significant reduction in disease activity, improvement in joint and skin symptoms, and a reduction in glucocorticosteroid use can be achieved.
Summary: Anifrolumab represents a novel approach in the treatment used in moderate to severe forms of SLE. This drug improves skin and joint symptoms, reduces disease activity, and reduces used doses of corticosteroids. It is well-tolerated and has a rapid therapeutic effect. It improves patients' quality of life. However, its safety in use in children, pregnant and breastfeeding women is unknown.
References
Galindo-Izquierdo, M., Bahamontes-Rosa, S., Sarto-Ferres, et al. (2025). Characteristics and clinical outcomes of patients with systemic lupus erythematosus initiating anifrolumab in a real-world setting in Spain (AZAHAR study): An observational study protocol. Lupus Science & Medicine, 12(1). https://doi.org/10.1136/lupus-2024-001486
Kuhn, A., Bonsmann, G., Anders, et al. (2015). The diagnosis and treatment of systemic lupus erythematosus. Deutsches Ärzteblatt International, 112(25), 423. https://doi.org/10.3238/arztebl.2015.0423
Cieplińska, A., Kuzio, A., & Ziojła-Lisowska. (2024). Nowe metody leczenia biologicznego w toczniu rumieniowatym układowym. Review of Medical Practice, 30(2), 61–68. https://doi.org/10.26399/rmp.v30.2.2024/a.cieplińska/a.kuzio/k.ziojła-lisowska
Aringer, M., Costenbader, K., Daikh, D., et al. (2019). 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis & Rheumatology, 71(9), 1400–1412. https://doi.org/10.1002/art.40930
Khan, M. A., Khan, F. H., Khan, et al. (2023). Role of anifrolumab in refractory cutaneous manifestations of lupus erythematosus: A case series and literature review. Cureus, 15(5). https://doi.org/10.7759/cureus.39553
Katarzyna, P. B., Wiktor, S., Ewa, D., et al. (2023). Current treatment of systemic lupus erythematosus: A clinician's perspective. Rheumatology International, 43(8), 1395–1407. https://doi.org/10.1007/s00296-023-05306-5
Canny, S. P., & Jackson, S. W. (2021). B cells in systemic lupus erythematosus: From disease mechanisms to targeted therapies. Rheumatic Diseases Clinics of North America, 47(3), 395. https://doi.org/10.1016/j.rdc.2021.04.006
Frankiewicz, T. (2022). Glikokortykosteroidy doustne–przewodnik lekarza praktyka. Medycyna i Życie, 9(1–4), 21–32.
Lever, E., Alves, M. R., & Isenberg, D. A. (2020). Towards precision medicine in systemic lupus erythematosus. Pharmacogenomics and Personalized Medicine, 39–49. https://doi.org/10.2147/PGPM.S205079
Jia, X., Lu, Y., Zheng, X., et al. (2024). Targeted therapies for lupus nephritis: Current perspectives and future directions. Chinese Medical Journal, 137(1), 34–43. https://doi.org/10.1097/CM9.0000000000002959
Piga, M., & Arnaud, L. (2021). The main challenges in systemic lupus erythematosus: Where do we stand? Journal of Clinical Medicine, 10(2), 243. https://doi.org/10.3390/jcm10020243
Athanassiou, P., & Athanassiou, L. (2023). Current treatment approach, emerging therapies and new horizons in systemic lupus erythematosus. Life, 13(7), 1496. https://doi.org/10.3390/life13071496
Yang, B., Zhao, M., Wu, H., et al. (2020). A comprehensive review of biological agents for lupus: Beyond single target. Frontiers in Immunology, 11, 539797. https://doi.org/10.3389/fimmu.2020.539797
Chan, J., Walters, G. D., Puri, P., et al. (2023). Safety and efficacy of biological agents in the treatment of systemic lupus erythematosus (SLE). BMC Rheumatology, 7(1), 37. https://doi.org/10.1186/s41927-023-00358-3
Peng, L., Oganesyan, V., Wu, H., et al. (2015, March). Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody. MAbs, 7(2), 428–439. https://doi.org/10.1080/19420862.2015.1007810
Cingireddy, A. R., Ramini, N., & Cingireddy, A. R. (2024). Evaluation of the efficacy and safety of anifrolumab in moderate-to-severe systemic lupus erythematosus. Cureus, 16(7). https://doi.org/10.7759/cureus.63966
Deeks, E. D. (2021). Anifrolumab: First approval. Drugs, 81(15), 1795–1802. https://doi.org/10.1007/s40265-021-01604-z
Baker, T., Sharifian, H., Newcombe, P. J., et al. (2024). Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials. Annals of the Rheumatic Diseases, 83(8), 1018–1027. https://doi.org/10.1136/ard-2023-225445
Liu, Z., Cheng, R., & Liu, Y. (2022). Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review. Frontiers in Immunology, 13, 996662. https://doi.org/10.3389/fimmu.2022.996662
Martín-Torregrosa, D., Mansilla-Polo, M., & Morgado-Carrasco, D. (2025). [Translated article] Use of anifrolumab in systemic lupus erythematosus, cutaneous lupus erythematosus, and other autoimmune dermatoses. Actas Dermo-Sifiliográficas, 116(1), T55–T67. https://doi.org/10.1016/j.ad.2024.05.024
Furie, R., Khamashta, M., Merrill, J. T., et al. (2017). Anifrolumab, an anti–interferon‐α receptor monoclonal antibody, in moderate‐to‐severe systemic lupus erythematosus. Arthritis & Rheumatology, 69(2), 376–386. https://doi.org/10.1002/art.39962
Chia, Y. L., Zhang, J., Tummala, R., et al. (2022). Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus. Rheumatology, 61(5), 1900–1910. https://doi.org/10.1093/rheumatology/keab704
Tang, W., Tummala, R., Almquist, J., et al. (2023). Clinical pharmacokinetics, pharmacodynamics, and immunogenicity of anifrolumab. Clinical Pharmacokinetics, 62(5), 655–671. https://doi.org/10.1007/s40262-023-01238-2
Kalunian, K. C. (2016). Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells? Lupus, 25(10), 1097–1101. https://doi.org/10.1177/0961203316652495
Loncharich, M. F., & Anderson, C. W. (2022). Interferon inhibition for lupus with anifrolumab: Critical appraisal of the evidence leading to FDA approval. https://doi.org/10.1002/acr2.11414
Shaw, K., Taylor, D., Sanchez-Melendez, S., et al. (2023). Improvement in mucosal discoid lupus erythematosus with anifrolumab. Clinical and Experimental Dermatology, 48(10), 1165–1167. https://doi.org/10.1093/ced/llad190
Jayne, D., Rovin, B., Mysler, E., et al. (2023). Anifrolumab in lupus nephritis: Results from second-year extension of a randomised phase II trial. Lupus Science & Medicine, 10(2), e000910. https://doi.org/10.1136/lupus-2023-000910
Deleuran, B., Troldborg, A., Remkus, L., et al. (2024). AB0987 anifrolumab treatment improves quality of life and decreases systemic corticosteroid use in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 83, 1809–1810. https://doi.org/10.1136/annrheumdis-2024-eular.600
Troldborg, A., Remkus, L., Eek, D., et al. (2024). Anifrolumab treatment improves patient-reported quality of life and decreases disease activity and corticosteroid use in patients with systemic lupus erythematosus: A qualitative study in Denmark. Lupus, 33(9), 962–973. https://doi.org/10.1177/09612033241261746
Bui, A., Patel, P., & Sanghavi, D. K. (2024). Anifrolumab. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK555979/
(Accessed November 25, 2025)
Drugs and Lactation Database (LactMed®) [Internet]. (2006–). Oral levonorgestrel. National Institute of Child Health and Human Development. https://www.ncbi.nlm.nih.gov/books/NBK501294/
(Updated June 15, 2025; accessed November 23, 2025)
Morand, E. F., Furie, R., Tanaka, Y., et al. (2020). Trial of anifrolumab in active systemic lupus erythematosus. New England Journal of Medicine, 382(3), 211–221. https://doi.org/10.1056/NEJMoa1912196
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Dawid Nowicki, Paulina Małyszczak, Małgorzata Muszyńska, Julia Surowaniec, Katarzyna Karaś, Sylwia Mroszczyk
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
